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Background: Leptospirosis is under-diagnosed by clinicians in many high-incidence countries, because
reference diagnostic tests are largely unavailable. Lateral flow assays (LFA) that use antigen derived from
heat-treated whole cell Leptospira biflexa serovar Patoc have the potential to improve leptospirosis
diagnosis in resource-limited settings.
Objectives: We sought to summarize estimates of sensitivity and specificity of LFA by conducting a
systematic review and meta-analysis of evaluations of the accuracy of LFA to diagnose human
leptospirosis.
Data sources: On 4 July 2017 we searched three medical databases.
Study eligibility criteriaArticles were included if they were a study of LFA sensitivity and specificity.
Participants: Patients with suspected leptospirosis.
Interventions: Nil.
Methods: For included articles, we assessed study quality, characteristics of participants and diagnostic
testing methods. We estimated sensitivity and specificity for each study against the study-defined case
definition as the reference standard, and performed a meta-analysis using a random-effects bivariate
model.
Results: Our search identified 225 unique reports, of which we included nine (4%) published reports
containing 11 studies. We classified one (9%) study as high quality. Nine (82%) studies used reference
tests with considerable risk of misclassification. Our pooled estimates of sensitivity and specificity were
79% (95% CI 70%e86%) and 92% (95% CI 85%e96%), respectively.
Conclusions: As the evidence base for determining the accuracy of LFA is small and at risk of bias, pooled
estimates of sensitivity and specificity should be interpreted with caution. Further studies should use
either reference tests with high sensitivity and specificity or statistical techniques that account for an
imperfect reference standard. M.J. Maze, Clin Microbiol Infect 2019;25:437
© 2018 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).f Tropical Medicine and Hy-
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Leptospirosis is a common cause of fever in tropical countries
and a re-emerging disease globally [1,2]. Diagnosis is challenging as
reference standard diagnostic tests such as Leptospira culture,
microscopic agglutination testing (MAT) and nucleic acid amplifi-
cation tests have imperfect sensitivity and specificity, areof Clinical Microbiology and Infectious Diseases. This is an open access article under
M.J. Maze et al. / Clinical Microbiology and Infection 25 (2019) 437e444438expensive, technically difficult and not widely available in areas
where leptospirosis is endemic [3]. Inexpensive and simple point-
of-care tests have been developed that detect anti-Leptospira IgM.
These have the potential to be deployed at both the district hospital
laboratory level and the health-centre level in low-resource set-
tings for the diagnosis of leptospirosis among febrile patients.
Lateral flow assays (LFA) that use whole cell leptospiral antigen
from the saprophytic Leptospira biflexa serovar Patoc strain Patoc I
are among the most promising point-of-care tests because they are
inexpensive and easy to use [4].
The accuracy of LFA has been evaluated in several studies with
varied estimates of both sensitivity and specificity. As such, a
summary of existing estimates of test performance and an under-
standing of sources of variation in the estimates is needed. We
conducted a systematic review andmeta-analysis to summarize the
sensitivity and specificity of LFA for diagnosing acute human
leptospirosis in patients with suspected leptospirosis, and to
identify potential reasons for variation in published estimates of
diagnostic accuracy between studies.
Methods
We conducted our systematic review in accordance with the
Preferred Reporting of Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [5]. We registered our review with the Inter-
national Prospective Register of Systematic Reviews (PROSPEROTable 1
Criteria for assessing bias in studies evaluating the accuracy of Leptospira biflexa serovar P
2017registration number CRD42018088566) and our protocol is avail-
able at https://www.crd.york.ac.uk/prospero/display_record.php?
RecordID¼88566.
After developing and piloting search terms, we ran our search
on 4 July 2017 using the databases Ovid Medline, Web of Science
and Scopus. In Ovid Medline we used the search terms and oper-
ators: ‘(Leptospirosis/*diagnosis OR Leptospirosis/*immunology OR
(Leptospir* AND Immunoglobulin M)) AND Humans AND (Sensi-
tivity and Specificity OR *Reference Standards).’ Search terms used
for the Web of Science and Scopus databases are shown in the
Supplementary material (Appendix S1). Articles were included if
they were a study of LFA sensitivity and specificity among patients
with fever. Evaluations of assays other than LFA and evaluations
performed in animals were excluded. Articles published in any
language and in any year were eligible for inclusion. A single author
(MJM) reviewed all abstracts and titles to determine which articles
may have relevant data. For those deemed potentially relevant two
authors (MJM and JAC) independently reviewed the full text of each
article. We assessed study quality using the revised Quality
Assessment of Diagnostic Accuracy Studies (QUADAS) criteria
known as QUADAS-2 (Table 1) [6]. Articles were graded in each
category according to the information included in the manuscript,
such that when methodological information was not included in
the manuscript the quality assessment was downgraded. We
graded study applicability in the domains of patient selection, use
of the index test and use of the reference test as shown in Table 2. Ifatoc lateral flow IgM assays for the diagnosis of leptospirosis, published before 4 July
Table 2
Criteria for assessing applicability in studies evaluating the accuracy of Leptospira biflexa serovar Patoc lateral flow IgM assays for the diagnosis of leptospirosis, published
before 4 July 2017
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attach a quality grade or applicability grade, we scored it as
‘unclear’.
Two authors (MJM and JAC) extracted data in duplicate using a
standardized data extraction sheet (see Supplementary material,
Table S1) and tabulated data in a Microsoft EXCEL spread sheet
(Microsoft Corporation, Redmond, WA, USA). We conducted meta-
analysis using the user written programme ‘midas’ in STATA 13.1
(StataCorp, College Station, TX, USA) [7]. We constructed forest
plots displaying estimated sensitivity and specificity from contin-
gency tables assuming that the reference test was 100% sensitive
and specific. Meta-performance characteristics were established
using a mixed-effects bivariate model. Publication bias was
assessed using Deeks' funnel plot asymmetry test [8,9]. Deeks'
funnel plot asymmetry test uses linear regression of log odds ratios
on the inverse root of effective sample sizes. A non-zero slope co-
efficient is suggestive of significant publication bias, or small study
bias (p < 0.10).Fig. 1. Study flow diagram for systematic review and meta-analysis of diagnostiResults
Our search identified 225 unique reports. Of these, 32 (14%)
were identified as potentially relevant on the basis of title and
abstract, and underwent full-text review. We determined that nine
(4%) articles were relevant and these were selected for final inclu-
sion (Fig. 1). The nine published reports contained data from 11
studies evaluating the accuracy of LFA.Study characteristics
Included studies were published from 2001 through 2015. Ten
(91%) of 11 studies were performed among patients with fever and
one (9%) was performed among patients with uveitis and was not
included in the meta-analysis [10]. Evaluations were performed
among participants from Brazil, India, Italy, Malaysia, the
Netherlands, Poland, Seychelles, Slovenia, Sri Lanka, Thailand, UK
and the USA. The sample matrix was serum in all studies. Eightc accuracy of leptospirosis lateral flow assays, published before 4 July 2017.
Table 3
Reference tests used in studies evaluating Leptospira biflexa serovar Patoc lateral flow IgM assays for the diagnosis of leptospirosis, published before 4 July 2017
Study first author,
number [reference]
Reference
test
Number of
Leptospira serovars
in reference test
Participants with reference
test performed on paired
serum samples
Reference test leptospirosis case definition
Smits 1a [12] MAT 1 100% at least a four-fold rise in MAT titre or single MAT titre160
Smits 2a [12] ELISA Not stated 0% Single antibody titre 80
Eapen [17] ELISA 2b 0% Single antibody titre 80
Sehgal [13] MAT þ culture 12 89% Positive culture, or seroconversion to an MAT titre 100, or
a four-fold rise in MAT titre, or a single MAT titre 400
Kannan [10] MAT Not stated 0% Single MAT titre 100
Limmathurotsakul [21] MAT þ culture 20 66% Positive culture or single MAT titre 400
Goris 1a [14] MAT þ IgM ELISA þ culture 14b Not statedc (i) Single MAT titre with a pathogenic serovar 160, (ii)
single IgM-ELISA titre 160, (iii) positive culture or (iv)
seroconversion/four-fold titre rise MAT or IgM ELISA (titre
20 to 80) in paired samples taken at least 2 days apart
Goris 2a [14] MAT þ IgM ELISA þ culture 14b Not statedc (i) Single MAT titre with a pathogenic serovar 160, (ii)
single IgM-ELISA titre 160, (iii) positive culture or (iv)
seroconversion/four-fold titre rise MAT or IgM ELISA (titre
20 to 80) in paired samples taken at least 2 days apart
Niloofa [15] MAT 13 28% Single MAT titre 400
Podgorsek [16] MAT 1b 6% Seroconversion to an MAT titre 100, or a four-fold rise in
MAT titre, or a single MAT titre 400
Eugene [18] MAT þ culture 1b 0% Positive culture or single MAT titre 100
Abbreviation: MAT, Leptospira microscopic agglutination test.
a Numbers refer to different data sets from within the same paper.
b Serovars included Leptospira biflexa serovar Patoc.
c Figures not stated but paper states that ‘In most cases only one sample was received per participant’.
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of two-gate design [11]. All studies reported that they performed
the LFA according to the manufacturers' instructions. One (9%)
study reported mean duration of symptoms and one (9%) study
reported the prevalence of use of antimicrobials before testing. The
leptospirosis reference test diagnostic criteria used in each study
are shown in Table 3. Two (18%) studies reported that 75% of
participants had paired serum samples tested for leptospirosis
[12,13]; five (45%) reported that <75% of participants had paired
serum samples tested, including two studies that did not provide
figures but stated that reference testing for ‘most’ participants was
performed on a single serum sample [14e16]; and four (36%) re-
ported that for all participants reference testing occurred on single
serum samples [10,12,17,18]. In setting diagnostic cut-offs for the
reference test, seven (64%) studies used MAT titres lower than
those recommended by the WHO [19]. Four (46%) studies used IgM
ELISA as a reference test. Ten (90%) studies considered the reference
standard to be perfect when conducting their analyses, and three
studies used latent class analysis, which does not assume the
reference standard to be perfectly accurate, to analyse their results
[20]. Two (18%) studies reported the serogroup of the infecting
Leptospira as determined by the reference test [14]. Further infor-
mation relating to study characteristics is included in the Supple-
mentary material (Table S2).
Study quality
The results of bias assessment are shown in Table 4. We
considered a single study to be of Grade 1 quality in each of the
four domains. We rated two (18%) studies as Grade 1 and nine
(82%) studies as Grade 2 for the reference test domain. This was
mostly (Table 3) because a single acute-phase serum sample for
serological testing was considered the reference test. We clas-
sified one (9%) study as Grade 3 in the patient selection domain
due to use of healthy participants from the population as con-
trols and one (9%) study as Grade 3 in the flow and timing
domain due to the use of different testing algorithms among
cases and controls [10,16]. We had applicability concerns about
the reference test chosen in five (45%) studies and in anadditional one (9%) study there was insufficient information to
assess this domain. We also had concerns about the applicability
of two (18%) of studies to our question within the patient se-
lection domain.Sensitivity and specificity estimates
The number of participants with, and without leptospirosis who
tested positive by LFA for each study is shown in Table 5. The
sensitivity and specificity of LFA, estimated in each study and the
pooled estimate, are shown in Fig. 2. In our meta-analysis we
included the ten (91%) studies that recruited patients with sus-
pected leptospirosis. The pooled estimate of sensitivity was 79%
(95% CI 70%e86%) and the pooled estimate of specificity was 92%
(95% CI 85%e96%). The study that we classified as of low risk of bias
in every domain [13] estimated the sensitivity of LFA as 53% (95% CI
41%e64%) and the specificity as 94% (95% CI 82%e98%). In the
funnel plot (Fig. 3) the regression line had a near vertical slope and
Deeks' test indicated funnel plot symmetry consistent with unbi-
ased publication (p 0.12). We excluded from our meta-analysis, the
study by Kannan et al. that estimated the sensitivity and specificity
of LFA among patients with uveitis as 70% (95% CI 54%e82%) and
69% (95% CI 53%e82%), respectively [10].Discussion
We systematically collated published literature on the sensi-
tivity and specificity of leptospirosis LFA point-of-care tests. We
identified that most evaluations were at risk of bias, predominantly
due to the use of reference test criteria that were likely to
misclassify participants. Of the studies included in our analysis,
there was substantial heterogeneity in estimated sensitivity and
specificity that appears to relate to study design, particularly the
choice of leptospirosis reference test, but may also relate to dura-
tion of illness, the predominant infecting Leptospira serovars and
variation in the production of LFA antigen. As such we consider our
pooled estimates for the sensitivity and specificity of LFA to be
unreliable and further robust evaluations are needed.
Table 4
Bias assessment of studies evaluating the accuracy of Leptospira biflexa serovar Patoc lateral flow IgM assays for leptospirosis published before 4 July 2017
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serovar Patoc lateral flow IgM assays varied from 55% to 93% [13,14]
and estimates of specificity varied from 57% to 99% [13,16]. Factors
relating to study design, particularly the variation in reference tests,
may account for the variation in apparent diagnostic accuracy. We
found that nine (82%) studies were at risk of bias due to concerns in
the reference test domain, with risk of misclassification of cases and
controls. There are well-documented accuracy concerns with
reference tests that make the choice of reference test challenging
[21,22]. Leptospira culture is thought to have close to 100% speci-
ficity, but it has been estimated to have a sensitivity of <10% [22,23].
Polymerase chain reaction of gene targets specific to pathogenic
Leptospira are specific for leptospirosis but typically have been
shown to have lower sensitivity than IgM serological assays [23,24]
with sensitivity values such as 36% when compared with MAT [25].
MAT serology is often considered the reference serological test for
diagnosis of leptospirosis [22], but also has imperfect sensitivity
and specificity. In a recent evaluation of MAT accuracy against
culture-confirmed leptospirosis cases, Goris et al. identified that
paired samples with at least 10 days between acute and convales-
cent samples had a sensitivity of 90% and 88% for 10e19 days and
20 days, respectively [22]. By comparison, the sensitivity ofTable 5
Extracted data from studies evaluating sensitivity and specificity of Leptospira biflexa ser
Study first author
[reference]
Assay manufacturer True positive False positive
n (%) n (%)
Smits 1a [12] KIT 116 (27.8) 28 (6.7)
Smits 2a [12] KIT 39 (43.3) 6 (6.7)
Eapen [17] Organon 54 (27.6) 6 (3.1)
Sehgal [13] KIT 37 (31.6) 3 (2.6)
Kannan [10] Zephyr 28 (36.8) 11 (14.5)
Limmathurotsakul [21] KIT 120 (32.3) 69 (18.6)
Goris 1a [14] BioMerieux 74 (5.3) 57 (4.1)
Goris 2a [14] Zephyr 100 (3.7) 56 (2.0)
Eugene [18] Zephyr 34 (40.5) 12 (14.3)
Niloofa [15] Zephyr 286 (32.2) 121 (13.6)
Podgorsek [16] Zephyr 29 (4.9) 7 (1.2)
Assay manufacturers: KIT, Royal Dutch Tropical Institute, Amsterdam, the Netherlands;
l'Etoile, France.
a Numbers refer to different data sets from within the same paper.diagnosing leptospirosis by using a high titre from a single serum
sample was low, at 6% within the first 10 days of illness. The
specificity of defining leptospirosis as at least a four-fold increase in
MATantibody titre between acute and convalescent serum samples
is considered to approximate 100% [22,23]. Defining leptospirosis
as a single high 400 titre is consistent with the WHO case defi-
nition but is imperfectly specific, especially where leptospirosis is
endemic. This is because Leptospira antibodies can persist in serum
for several years after acute infection [26]. Although case defini-
tions using single antibody titres of 160, 400 and  800 may be
appropriate for clinical diagnosis [19,22,27], their use as a reference
standard in diagnostic test evaluation may lead to misclassification
of cases and controls and biased estimates of sensitivity and spec-
ificity of novel diagnostic tests. Only two (18%) studies tested pre-
dominantly paired serum samples when conducting reference
testing for disease classification and potential misclassification was
compounded by the variation in the reference test titre used to
classify leptospirosis. ELISA is widely used as a screening test for the
diagnosis of leptospirosis; however. the pooled estimates of
sensitivity and specificity of ELISA from a systematic review and
meta-analysis were 78% (95% CI 77%e79%) and 91% (95% CI 91%e
92%), respectively [28]. In addition there was significantovar Patoc lateral flow IgM assays published before 4 July 2017
True negative False
negative
Sensitivity Specificity
n (%) n (%) (95% CI) (95% CI)
255 (61.0) 19 (4.5) 0.86 (0.79e091) 0.90 (0.86e0.93)
41 (45.6) 4 (4.4) 0.91 (0.78e0.97) 0.87 (0.74e0.94)
131 (66.8) 5 (2.6) 0.90 (0.80e0.95) 0.96 (0.92e0.99)
44 (37.6) 33 (28.2) 0.53 (0.54e0.82) 0.94 (0.82e0.98)
25 (32.9) 12 (15.8) 0.70 (0.42e0.69) 0.69 (0.53e0.82)
165 (44.5) 17 (4.6) 0.88 (0.81e0.92) 0.71 (0.64e0.76)
1235 (88.2) 34 (2.4) 0.69 (0.59e0.77) 0.96 (0.94e0.97)
2495 (91.3) 83 (3.0) 0.55 (0.47e0.62) 0.98 (0.97e0.98)
32 (38.1) 6 (7.1) 0.85 (0.70e0.93) 0.73 (0.58e0.84)
405 (45.6) 76 (8.6) 0.79 (0.75e0.83) 0.77 (0.73e0.80)
547 (92.7) 7 (1.2) 0.81 (0.65e0.90) 0.99 (0.97e0.99)
Organon, Oss, the Netherlands; Zephyr Diagnostics, Goa, India; BioMerieux, Marcy-
Key: The squares indicate the point estimate of sensitivity or specificity from 
each study, and the line indicates the 95% confidence intervals. The vertical 
dotted line indicates the point meta-estimate of sensitivity or specificity, and 
the diamond indicates the 95% confidence intervals 
Fig. 2. Forest plot of sensitivity and specificity of Patoc antigen lateral flow assays for the diagnosis of leptospirosis, published before 4 July 2017.
M.J. Maze et al. / Clinical Microbiology and Infection 25 (2019) 437e444442heterogeneity across studies that was not fully explained by disease
stage, antigen used and antibody detected. The imperfect accuracy
and significant heterogeneity suggest that use of ELISA as a refer-
ence test will be likely tomisclassify the disease state of some study
participants.Key:  1/root(ESS) indicates the invers
Fig. 3. Funnel plot for a meta-analysis of Leptospira biflexa serovar Patoc lateral flow IgM
regression test of funnel plot asymmetry.In addition to the choice of reference test, the variations in
estimated accuracy of LFA may reflect varying performance at
different stages of the illness. Of the few studies reporting the
duration of illness, Sehgal et al. found that among participants in
the Andaman Islands LFA had a sensitivity of 53% during the firste root of the effective sample size 
assays for detecting leptospirosis published before 4 July 2017 and Deeks' weighted
M.J. Maze et al. / Clinical Microbiology and Infection 25 (2019) 437e444 443week of illness, and 86% during the second through fourth weeks of
illness [13]. The corresponding specificity was 94% during the first
week and 89% from the second through fourth weeks [29]. Goris
et al. demonstrated that for two LFA, sensitivity increased from
42%e62% during days 0e4 after onset, to 65%e75% during days
5e10 after onset, and 72%e81% during days 11e20 after onset [14].
The single study investigating LFA accuracy among patients with
uveitis found accuracy values among the lowest of the studies. This
may be due to the wide differential diagnoses of uveitis, the vari-
able interval between leptospirosis infection and uveitis, and the
use of immunosuppressants as treatment for uveitis. The
geographic setting of the study population may influence test
performance through variation in infecting Leptospira serovars and
variation in the type and prevalence of diseases other than lepto-
spirosis that cause fever. It was notable that the one report that
reported serogroup of the infecting Leptospira found that LFA ac-
curacy was higher among participants infected with Leptospira
serogroup Icterohaemorrhagiae [14]. One study included in our
review noted variation in assay performance over time, which they
thought may be due to variability of the antigen among assay
production lots [14].
Our meta-analysis has several limitations that influence inter-
pretation. We may not have identified all relevant articles through
an incompletely comprehensive search strategy that used subject
headings or free text terms individually to describe each concept,
as well as use of limiting terms such as ‘humans’ and ‘sensitivity
and specificity’. In addition, we may have missed studies that were
published in journals not indexed by Ovid Medline, Scopus or Web
of Science, as well as studies that were not published. Combining
all studies into a single estimate of sensitivity and specificity may
be misleading as there was substantial variation in both study
design and in the populations from which participants were
drawn. Our meta-analysis assumed that the reference test had
100% sensitivity and specificity. The reference tests used in most
studies included in our meta-analysis have not had their sensi-
tivity and specificity adequately determined. Under these cir-
cumstances conventional sensitivity and specificity estimates are
likely to underestimate the accuracy of point-of-care diagnostic
tests [30,31]. In the context of imperfect reference standards, other
authors have used latent class analyses to estimate sensitivity and
specificity [23,30e32]. Latent class analysis requires that there are
at least four independent diagnostic tests to be able to identify
two latent classes [31]. This was not possible in our meta-analysis
as most studies did not include a sufficient number of indepen-
dent diagnostic assays.
On the assumption that the true sensitivity and specificity of LFA
is at least as high as our pooled estimate, LFA may have a role as a
screening assay. In studies from Southeast Asia and Africa, where
leptospirosis is endemic, the prevalence of acute leptospirosis has
been as high as 10% among febrile patients presenting for health-
care [33,34]. Assuming 10% prevalence of acute leptospirosis among
patients tested with LFA, the negative predictive value would be
98% (95% CI 96%e99%), with 2% (95% CI 1%e4%) of leptospirosis
cases missed. This suggests that in high incidence settings that
clinicians could use a negative LFA result to exclude leptospirosis,
except during the first few days of illness when all serological as-
says may have lower sensitivity and negative predictive values [24].
However, only 48% (95% CI 30%e66%) of those who tested positive
with LFA would truly have leptospirosis. Unless there are suitable
confirmatory assays available there is considerable risk that intro-
duction of LFAwould result in over-diagnosis of leptospirosis. Over-
diagnosis may have implications for individual patients in whom
diseases that are also common in countries with high leptospirosis
incidence and that require specific treatment, such as rickettsiosis,
may be falsely discounted.A key finding of our study is that the evidence base for esti-
mating the sensitivity and specificity of LFA is small and at risk of
bias. Further studies are needed. Future studies should use a
reference standard with sensitivity and specificity close to 100% or
statistical analyses that manage the absence of a perfect reference.
We suggest that future evaluations of point-of-care tests should
consider the use of MAT on paired serum samples, PCR and culture
as leptospirosis reference tests. In addition, as even a combination
of these tests is unlikely to have 100% sensitivity, statistical
methods that account for imperfect reference test accuracy, such as
latent class analysis, should be considered [23]. Latent class ana-
lyses assume that the observations are independent within each of
the two latent classes [31]. Estimates of sensitivity and specificity
are sensitive to violations of this assumption, and therefore esti-
mates obtained by latent class analyses should also be interpreted
cautiously, particularly if checks of the validity of the assumption
are not reported [31,35].
Estimates of the sensitivityand specificity varied from53% to95%
and 57% to 99%, respectively, with study design, particularly choice
of the leptospirosis reference test, and features of the study popu-
lation contributing to the variation. Our meta-estimates of sensi-
tivity and specificity should be interpretedwith caution, but suggest
that LFA may have a limited role as a screening test in endemic
settings, if appropriate confirmatory testing is available. Future
studies evaluating point-of-care diagnostic tests should optimize
the sensitivity and specificity of the leptospirosis reference test and
consider statistical methods to manage imperfect reference tests.
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